The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma.
 
Michael David Kinnaman
Consulting or Advisory Role - Cardinal Health
 
Simone Zaccaria
No Relationships to Disclose
 
Alvin Makohon-Moore
No Relationships to Disclose
 
Gunes Gundem
No Relationships to Disclose
 
Juan E. Arango Ossa
No Relationships to Disclose
 
Nancy Bouvier
No Relationships to Disclose
 
Filemon S. Dela Cruz
No Relationships to Disclose
 
Meera Hameed
No Relationships to Disclose
 
Julia Lynne Glade Bender
Research Funding - Bayer (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on a T lympboblastic lymphoma cell line, CUTLL1
Travel, Accommodations, Expenses - Amgen (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Eisai; Merck; SpringWorks Therapeutics
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; Ayala Pharmaceuticals; Bayer; C4 Therapeutics; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; Foghorn Therapeutics; Kowa Pharmaceutical; Lilly; Medpacto; Mundipharma; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Paul A. Meyers
Honoraria - Eastern Pulmonary Conference (I); France Foundation (I)
Consulting or Advisory Role - Boehringer Ingelheim (I); Salarius Pharmaceuticals
Speakers' Bureau - France Foundation (I); Genentech/Roche (I)
Research Funding - Boehringer Ingelheim (I)
Travel, Accommodations, Expenses - InterMune (I); Takeda
 
Elli Papaemmanuil
Leadership - Isabl Technologies; Isabl Technologies
Stock and Other Ownership Interests - Isabl Technologies
Honoraria - Celgene; Novartis
Speakers' Bureau - Illumina
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene; Novartis
 
Andrew Kung
Leadership - Isabl Technologies
Stock and Other Ownership Interests - Imago Pharma; Isabl Technologies
Consulting or Advisory Role - DarwinHealth; Emendo; Imago Pharma; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing and royalty from bioluminescence imaging models
 
Christine A Iacobuzio-Donahue
Research Funding - Bristol Myers Squibb Foundation